Volume 54, Issue 4, Pages (October 2008)

Slides:

Advertisements

Similar presentations

Volume 61, Issue 5, Pages (May 2012)

Advertisements

The PSA Era is not Over for Prostate Cancer

Volume 54, Issue 2, Pages (August 2008)

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Volume 58, Issue 4, Pages (October 2010)

Reversible, Non-Barrier Male Contraception: Status and Prospects

Testosterone Therapy in Men With Prostate Cancer

Volume 62, Issue 5, Pages (November 2012)

Volume 66, Issue 4, Pages (October 2014)

Testosterone and Prostate Cancer: Revisiting Old Paradigms

Volume 73, Issue 6, Pages (June 2018)

Control of Prostate Cancer by Transrectal HIFU in 227 Patients

Volume 51, Issue 4, Pages (April 2007)

Volume 53, Issue 5, Pages (May 2008)

Who Benefits from Neoadjuvant or Adjuvant Hormone Therapy?

Volume 52, Issue 3, Pages (September 2007)

Meric Sengoz, Ufuk Abacioglu, İlknur Cetin, Levent Turkeri

Prostate Cancer Epidemic in Sight?

Volume 52, Issue 4, Pages (October 2007)

Volume 45, Issue 4, Pages (April 2004)

Failure to Achieve Castration Levels in Patients Using Leuprolide Acetate in Locally Advanced Prostate Cancer Olav Erich Yri, Trine Bjoro, Sophie D.

Volume 63, Issue 4, Pages (April 2013)

The Importance of Transurethral Resection in Managing Patients With Urothelial Cancer in the Bladder: Proposal for a Transurethral Resection of Bladder.

Volume 52, Issue 3, Pages (September 2007)

Volume 54, Issue 4, Pages (October 2008)

What is New in Hormone Therapy for Prostate Cancer in 2007?

Volume 53, Issue 4, Pages (April 2008)

Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?

Prostate Cancer Detection: A View of the Future

Ongoing Gleason Grade Migration in Localized Prostate Cancer and Implications for Use of Active Surveillance Adam B. Weiner, Ruth Etzioni, Scott E. Eggener

Volume 56, Issue 2, Pages (August 2009)

Prostate Cancer Management: What Does the Future Hold?

Volume 66, Issue 3, Pages (September 2014)

Counselling the Prostate Cancer Patient

Prostate Cancer Epidemic in Sight?

The PSA Era is not Over for Prostate Cancer

Volume 61, Issue 5, Pages (May 2012)

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Volume 58, Issue 1, Pages 1-7 (July 2010)

Training in Percutaneous Nephrolithotomy—A Critical Review

Volume 68, Issue 4, Pages (October 2015)

Is It Necessary to Detect All Prostate Cancers in Men with Serum PSA Levels

RANK Ligand-targeted Therapy: A Novel Approach to Prevent Bone Loss and Fractures in Men with Prostate Cancer Matthew R. Smith European Urology Supplements

Prostate-Specific Antigen Kinetics and Outcomes in Patients with Bone Metastases from Castration-Resistant Prostate Cancer Treated with or Without Zoledronic.

Volume 50, Issue 5, Pages (November 2006)

CyberKnife in the Treatment of Prostate Cancer: A Revolutionary System

Prostate Specific Antigen Doubling Time as Auxiliary End Point in Hormone Refractory Prostatic Carcinoma Hans-Peter Schmid, Rudolf Morant, Jürg Bernhard,

Optimal Control of Testosterone: A Clinical Case-Based Approach of Modern Androgen- Deprivation Therapy Bertrand Tombal, Richard Berges European Urology.

The Importance of Testosterone Control in Prostate Cancer

Testicular Cancer Variations in Time and Space in Europe

Optimal Testosterone Control and Eligard®

Volume 53, Issue 1, Pages (January 2008)

Neal Shore European Urology Supplements

The 20-Yr Outcome in Patients with Well- or Moderately Differentiated Clinically Localized Prostate Cancer Diagnosed in the Pre-PSA Era: The Prognostic.

Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?

Long-Term Hormonal Therapy: Who Would Benefit?

Volume 59, Issue 4, Pages (April 2011)

Thomas Steuber, Matthew Frank O'Brien, Hans Lilja European Urology

New Trends in Managing the Prostate Cancer Patient

Improving Outcomes in Prostate Cancer: Time to Tackle Bone Disorders

Volume 54, Issue 5, Pages (November 2008)

Martin Michel, Jean de la Rosette European Urology Supplements

Role of Luteinising Hormone Releasing Hormone (LHRH) Agonists and Hormonal Treatment in the Management of Prostate Cancer P. Mongiat-Artus, P. Teillac

Richard Berges European Urology Supplements

Volume 68, Issue 5, Pages (November 2015)

Edith Canby-Hagino, Javier Hernandez, Timothy C. Brand, Ian Thompson

Volume 53, Issue 2, Pages (February 2008)

Bertrand Tombal, Richard Berges

Volume 51, Issue 5, Pages (May 2007)

Appropriate Castration with Luteinising Hormone Releasing Hormone (LHRH) Agonists: What is the Optimal Level of Testosterone? B. Tombal European Urology.

Presentation transcript:

Volume 54, Issue 4, Pages 805-815 (October 2008) Degarelix: A Novel Gonadotropin-Releasing Hormone (GnRH) Receptor Blocker— Results from a 1-yr, Multicentre, Randomised, Phase 2 Dosage-Finding Study in the Treatment of Prostate Cancer Hendrik Van Poppel, Bertrand Tombal, Jean J. de la Rosette, Bo-Eric Persson, Jens-Kristian Jensen, Tine Kold Olesen European Urology Volume 54, Issue 4, Pages 805-815 (October 2008) DOI: 10.1016/j.eururo.2008.04.065 Copyright © 2008 European Association of Urology Terms and Conditions

Fig. 1 Study design. A total of 180 patients were to be enrolled for a study period of 13 28-d treatment cycles made up of one injection of an initial dose (200mg or 240mg of degarelix) and 12 monthly injections of a maintenance dose (80mg, 120mg, or 160mg of degarelix). European Urology 2008 54, 805-815DOI: (10.1016/j.eururo.2008.04.065) Copyright © 2008 European Association of Urology Terms and Conditions

Fig. 2 Patient flow. Numbers in parentheses denote the percentage of randomised patients of that treatment group. Insufficient testosterone response was defined as one testosterone value >1.0ng/ml or two consecutive values >0.5ng/ml after 1 mo of treatment and onwards. European Urology 2008 54, 805-815DOI: (10.1016/j.eururo.2008.04.065) Copyright © 2008 European Association of Urology Terms and Conditions

Fig. 3 Changes from baseline in testosterone, prostate-specific antigen (PSA), luteinising hormone (LH), dihydrotestosterone (DHT), and follicle-stimulating hormone (FSH) in the group that received an initial dose of 240mg of degarelix during the first 14 d. Baseline values: testosterone 4.07ng/ml; PSA 31.8ng/ml; LH 5.30IU/l; DHT 340pg/ml; FSH 8.85IU/l. European Urology 2008 54, 805-815DOI: (10.1016/j.eururo.2008.04.065) Copyright © 2008 European Association of Urology Terms and Conditions

Fig. 4 Serum (A) testosterone and (B) prostate-specific antigen levels (ng/ml) during the study in the six treatment groups. European Urology 2008 54, 805-815DOI: (10.1016/j.eururo.2008.04.065) Copyright © 2008 European Association of Urology Terms and Conditions